NSE · RUBICON
Rubicon Research Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹390 Cr with net profit ₹70 Cr — a 17.96% net margin, versus 12.32% the period before.
Shareholding
As of 2026-06-30
- Promoter59.76%
- Public23.3%
- FII7.52%
- DII9.43%
43,254 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.79× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #4 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,593 Cr | 84.68 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,281 Cr | 158.51 | 9.37 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,809 Cr | 113.86 | 4.03 | 9.92% | 15.98% |
| Rubicon Research Limited(this company) | ₹25,194 Cr | 326.75 | 19.59 | 19.14% | 14.07% |
| Eris Lifesciences Limited | ₹19,864 Cr | 69.59 | 5.09 | 15.87% | 19.89% |
| Caplin Point Laboratories Ltd. | ₹19,786 Cr | 116.31 | 5.52 | 17.88% | 29.32% |
| Shilpa Medicare Ltd. | ₹11,872 Cr | 110.16 | 4.58 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,780 Cr | 79.5 | 3.9 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,110 Cr | 166.67 | 6.54 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,861 Cr | 142.34 | 4.07 | 8.95% | 11.15% |
AI analysis
AI-generated · google/gemini-2.5-flashRubicon Research Limited has a market capitalization of Rs 25003 Cr. The company reported a revenue of Rs 1296.22 Cr with a profit margin of 14.07%. Its Price-to-Earnings (PE) ratio stands at 323.03, and it has a Book Value of Rs 77.93. Earnings Per Share (EPS) is Rs 14.92. The company's Return on Equity (ROE) is 19.14% and Return on Capital Employed (ROCE) is 22.5629%. The debt-to-equity ratio is 0.91. The 52-week high for the share price was Rs 1527 and the 52-week low was Rs 570.75. The dividend yield is 10%.
Positives
- +Revenue growth of 50.4% to Rs 1296.22 Cr indicates strong sales performance.
- +The Return on Capital Employed (ROCE) is 22.5629%, suggesting efficient use of capital.
- +The trailing twelve-month profit margin is 14.07%.
- +Promoter shareholding is at 59.7573% as of June 30, 2026, indicating significant insider confidence.
- +The company has a dividend yield of 10% based on current share price and dividend payouts.
Negatives
- −The Price-to-Earnings (PE) ratio of 323.03 is high relative to its EPS of Rs 14.92.
- −The debt-to-equity ratio is 0.91, which suggests a notable level of financial leverage.
- −Promoter holding has decreased from 59.9868% in October 2025 to 59.7573% in June 2026.
Financial Performance
Rubicon Research Limited recorded a revenue of Rs 1296.22 Cr, representing a growth of 50.4%. The net profit margin for the company is 14.07%. Over the last twelve months, the company's EPS was Rs 14.92. Quarterly revenue has shown an increasing trend, rising from Rs 313.4 Cr in Dec 2024 to Rs 513.92 Cr in Mar 2026. Net profit also increased from Rs 38.07 Cr in Dec 2024 to Rs 76.79 Cr in Mar 2026.
Profitability & Returns
The company's Return on Equity (ROE) is 19.14% and Return on Capital Employed (ROCE) is 22.5629%. The profit margin stands at 14.07%. In the latest quarter ending March 2026, the company reported an EBITDA of Rs 109.05 Cr and a net profit of Rs 76.79 Cr from a revenue of Rs 513.92 Cr.
Balance Sheet
Rubicon Research Limited has a debt-to-equity ratio of 0.91, indicating reliance on debt in its capital structure. The Book Value per share is Rs 77.93. The company's market capitalization is Rs 25003 Cr.
Ownership & Pledges
As of June 30, 2026, promoter holding in Rubicon Research Limited stood at 59.7573%. FIIs held 7.5172% of the shares, while DIIs held 9.4285%. Public shareholding was 23.297%. Total institutional holding was 16.9457%. There are no promoter shares reported as pledged.
Regulatory & Surveillance
Rubicon Research Limited is not currently noted as being under any regulatory surveillance frameworks. There are no reported pledges by promoters for their shareholding, with promoter pledge at 0% for the period ending June 30, 2026.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.